Here's Why NRx Pharmaceuticals Stock Dropped Monday

Here's Why NRx Pharmaceuticals Stock Dropped Monday

Shares of COVID-19 stock NRx Pharmaceuticals (NASDAQ: NRXP) fell 24% Monday after soaring last week. Last week, NRX Pharmaceuticals stock nearly tripled in response to a positive clinical trial readout for its lead candidate, Zyesami, and a potential solution to a serious logistics problem. On July 19, NRx Pharmaceuticals rose after reporting positive biomarker data from a late-stage clinical trial with Zyesami.